Despite improvements in radiographic diagnostic techniques, including magnetic resonance imaging (MRI), the misdiagnosis of multiple sclerosis (MS) is a common problem that can lead to treatment-related and psychosocial morbidity.
“Today, MRI is the best biomarker we have, but the specificity is not 100%. Even in the hands of experts who develop these criteria, you can only distinguish MS from other criteria 87% of the time among experienced researchers using formal criteria—and that’s actually high,” said John R. Corboy, MD, FAAN, Co-Director, Rocky Mountain Multiple Sclerosis Center, University of Colorado, Aurora, at the 2016 American Academy of Neurology meeting.
“In real-world practice, however, this formal MRI criteria is not in general use,” he added.
A number of conditions can be misdiagnosed as MS, including migraine alone or in combination with other diagnoses, fibromyalgia, nonspecific or nonlocalizing neurologic symptoms with abnormal MRI results, conversion or psychogenic disorder, and neuromyelitis optica spectrum disorder.
The diagnostic potential of MRI has advantages and pitfalls, Dr Corboy explained. “We’re living in the era of effective therapy,” he said. “We can start highly effective therapy that we think has a significant opportunity to limit the likelihood of developing disability over time.”
“On the flip side, however, there’s fear that if you miss a diagnosis—or don’t diagnose fast enough—you’ll be contacted by a lawyer,” he added.
There can also be inducement on the part of physicians in the form of money for in-office infusions. “Ultimately, regardless of the motivations, if there’s misdiagnosis and there’s treatment, there is mistreatment,” said Dr Corboy.
According to Dr Corboy, misdiagnosing MS can be attributed to several factors, including:
Furthermore, significant harm can befall patients who are mistreated. For example, one patient with relapsing-remitting MS died from progressive multifocal leukoencephalopathy after receiving natalizumab (Tysabri) and interferon beta-1a as part of a clinical trial, Dr Corboy reported.
“You’re not only treating the wrong disease, but you’re exposing those patients to potentially expensive and/or potentially deadly medications,” Dr Corboy emphasized.
One study of patients misdiagnosed with MS showed that 70% of them had received disease-modifying therapies, and >30% had suffered a significant level of morbidity. Furthermore, >50% of the patients had been misdiagnosed for a “prolonged period of time,” suggesting that “once someone gets misdiagnosed with MS, it becomes very difficult to ‘un-ring that bell,’” said Dr Corboy.
According to Dr Corboy, improving the diagnostic accuracy of MS starts with the following measures:
Stay up to date with the latest news in neurology by subscribing to receive the free VBCN e‑Newsletter.